The field has also witnessed the emergence of novel therapeutic strategies targeting the adipokine-hepatokine axis, with mechanistic studies elucidating the roles of key mediators like adiponectin, leptin, and FGF21 in hepatic steatosis, inflammation, and fibrosis. Here, LEP is linked to fatty liver disease.